Breaking AI & Tech News Analyzed

The Lead: Biotech Barbie's Mission to Edit Human DNA Cathy Tie, a Canadian entrepreneur known as "Biotech Barbie," is pursuing a controversial mission to genetically modify embryos to prevent hereditary diseases, following in the footsteps of her ex-husband He Jiankui, who served prison time for creating the world's first gene-edited babies. Despite global bans on germline gene editing for reproductive purposes, Tie aims to conduct this work openly with regulatory approval and venture capital funding. The Technical Breakthrough: Gene Editing Made Accessible Since the invention of the Crispr-Cas9 gene editing tool in 2012, the technical process of altering DNA has become relatively straightforward. "The hardest thing about genetically engineering a baby is getting permission to do it; the technical part is not particularly complicated," the article explains. The process is compared to using "find, copy, cut and paste functions on a computer" and doesn't require extensive expertise in molecular biology. Germline gene editing—altering eggs, sperm, or early embryos—is particularly significant because changes are passed down to future generations, potentially altering human evolution permanently. This is why such procedures are banned in the UK, US, and China, with international agreement against research that could result in gene-edited babies. The Financial Landscape: Billionaires Investing in Genetic Engineering Money is flowing into human genetic engineering, with some of the world's richest men investing in companies pursuing similar goals. Preventive, a gene editing startup launched in October 2025 with the aim of "preventing disease before birth," has attracted investment from OpenAI's Sam Altman, his husband Oliver Mulherin, and Coinbase CEO Brian Armstrong. Armstrong has coined the term "the Gattaca stack"—referencing the dystopian film about a genetically engineered society—which includes technologies for "disease prevention, or enhancement" of babies. This suggests a growing interest not just in preventing diseases but in enhancing human traits. Preimplantation genetic testing (PGT), already common in the US fertility treatments, allows parents to "choose the embryo that best matches what you want," with companies like Nucleus Genomics advertising on subways with the tagline "Have your best baby." The Global Impact: A New Biological Arms Race? "There's a big geopolitical component to this," Tie states, referring to the growing interest in genetic engineering. China, where Tie was banned from entering, has already demonstrated what gene editing can do—Chinese researchers made the first edits to human embryos in 2015, and Tie's ex-husband He Jiankui created the first gene-edited babies, twin girls known as Lulu and Nana. Since his release from prison in 2022, He has become an unlikely social media star with close to 150,000 followers on X, making unrepentant posts about "designer babies" being "inevitable." Meanwhile, China's biotechnology ambitions have expanded, with Premier Li Qiang announcing new regulations emphasizing "the need to promote innovative development" and "accelerate R&D; and commercialization." In response to China's announcement, Tie posted: "Welcome to the dawn of the biological arms race." The Future Outlook: Inevitable Genetic Modification "Biology is a double-edged sword – it can be used for good, to heal people, or it can be used for bad," Tie explains. "Stopping this research will only drive bad actors to do it secretively. There is no way to stop this. This is inevitable. The only way to proceed is to do it openly and transparently." Tie named her first human gene-editing company the Manhattan Project, drawing a parallel between the nucleus of the atom and the nucleus of the cell. "In the 20th century, we understood the nucleus of the atom very well, and we learned some very difficult lessons via weapons and wars," she says. "I don't want to see the same happen with the second nucleus." Despite her declared commitment to openness, much of Tie's work remains shrouded in secrecy. Her first company, the Manhattan Project, has since shut down due to what she calls a "fundamental mistake" in choosing a co-founder. She has since launched Origin Genomics, continuing her pursuit of genetic modification of embryos.

Researchers at Rothamsted Research in Harpenden, Hertfordshire, have made a groundbreaking discovery in the field of food safety. By utilizing Crispr genome editing, they have successfully developed wheat that can be used to make bread with reduced levels of acrylamide, a toxic compound classified as a probable carcinogen.The innovation lies in the reduction of free asparagine, an amino acid in wheat that converts into acrylamide when bread is toasted, fried, or baked. Field trials over two years demonstrated that gene-edited wheat can have significantly lower concentrations of free asparagine without impacting crop yields. This translates into lower acrylamide formation in food products, making toasted bread safer for consumption.In tests, bread and biscuits made from the edited wheat showed substantially reduced acrylamide levels, with some bread samples having concentrations below detectable limits even after toasting. The Crispr editing targeted the gene responsible for asparagine production, achieving a reduction of up to 93% in free asparagine in dual-edited lines.Compared to conventional methods that achieved a 50% reduction in free asparagine but resulted in a 25% yield penalty, the Crispr-edited wheat offers a more efficient and effective solution. Dr. Navneet Kaur, a lead researcher, highlighted the potential of Crispr technology to deliver precise, beneficial changes in crop genetics, emphasizing the importance of supportive regulatory frameworks to unlock benefits for agriculture and food systems.The UK has become a global hub for gene editing research since Brexit, with the Genetic Technology (Precision Breeding) Act of 2023 facilitating the development and marketing of genetically modified crops. However, the future of these advancements may be influenced by negotiations with the EU over sanitary and phytosanitary agreements.Prof. Nigel Halford, who led the study, noted that low-acrylamide wheat could help food businesses meet safety standards without compromising product quality or incurring major costs, ultimately reducing consumers' dietary exposure to acrylamide.